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Background: Cabergoline is typically effective for treating prolactinomas; however, some patients display cabergoline resis-
tance, and the early characteristics of these patients remain unclear. We analyzed early indicators predicting long-term response 
to cabergoline.
Methods: We retrospectively reviewed the cases of 44 patients with macroprolactinomas who received cabergoline as first-line 
treatment; the patients were followed for a median of 16 months. The influence of various clinical parameters on outcomes was 
evaluated.
Results: Forty patients (90.9%) were treated medically and displayed tumor volume reduction (TVR) of 74.7%, a prolactin nor-
malization (NP) rate of 81.8%, and a complete response (CR; TVR >50% with NP, without surgery) rate of 70.5%. Most patients 
(93.1%) with TVR ≥25% and NP at 3 months eventually achieved CR, whereas only 50% of patients with TVR ≥25% without 
NP and no patients with TVR <25% achieved CR. TVR at 3 months was strongly correlated with final TVR (R=0.785). Patients 
with large macroadenomas exhibited a low NP rate at 3 months, but eventually achieved TVR and NP rates similar to those of pa-
tients with smaller tumors. Surgery independently reduced the final dose of cabergoline (β=−1.181 mg/week), and two of four 
patients who underwent surgery were able to discontinue cabergoline.
Conclusion: Determining cabergoline response using TVR and NP 3 months after treatment is useful for predicting later out-
comes. However, further cabergoline administration should be considered for patients with TVR >25% at 3 months without NP, 
particularly those with huge prolactinomas, because a delayed response may be achieved. As surgery can reduce the cabergoline 
dose necessary for successful disease control, it should be considered for cabergoline-resistant patients.
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INTRODUCTION
Prolactinomas are the most frequent functioning pituitary ade-
nomas, comprising approximately 40% of pituitary tumors 
[1,2]. Their prevalence in the general adult population has 
been reported to range from 100 to 625 cases per million peo-
ple [3,4]. Prolactinomas cause symptoms via two mechanisms, 
hormonal effects via hyperprolactinemia and mass effects via 
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tumor expansion [1,5]. Hyperprolactinemia causes sexual and 
gonadal dysfunction, such as decreased libido, amenorrhea, 
erectile disorder, and infertility, as well as galactorrhea. Mass 
effects in patients with macroadenomas include bilateral hemi-
anopsia, headache, hypopituitarism, and cranial neuropathy.
 Dopamine agonists (DAs) are well-established first-line 
treatments for prolactinomas that can induce tumor shrinkage 
and normalization of prolactin (PRL) levels (NP) [1,5]. These 
agonists include bromocriptine, pergolide, cabergoline (CAB), 
and quinagolide, but only bromocriptine and CAB are current-
ly available in Korea. Bromocriptine, which was introduced 
clinically in the 1980s, is a traditional drug for the treatment of 
prolactinomas [1,6]. However, CAB, which was introduced 
more recently, is used more commonly than bromocriptine. 
CAB is a selective agonist of the D2 receptor, which is related 
to the resolution of hyperprolactinemia, contrary to bromocrip-
tine, which has partial affinity for the D1 receptor and affinity 
for the D2 receptor [6]. This agent has superior tolerability and 
convenience for patients, as well as higher rates of tumor 
shrinkage and control of hyperprolactinemia compared with 
bromocriptine [7,8]. It has also been shown to be effective in 
patients with bromocriptine-intolerant or bromocriptine-resis-
tant prolactinomas [9,10].
 However, a considerable proportion of patients display re-
sistance to CAB. CAB treatment was reported to induce NP 
and successful tumor reduction in 61% to 92% and 55% to 
100% of patients with prolactinomas, respectively [1]. Molitch 
[11] defined pharmacologic resistance in prolactinoma as a 
failure to achieve NP and/or to decrease tumor size by ≥50%, 
and described the rate of CAB resistance as 10% to 15% in 
terms of PRL levels and tumor size. The treatment of patients 
with CAB resistance remains challenging, although a few arti-
cles have suggested that surgical debulking or high-dose CAB 
therapy can be helpful for patients with resistance to DAs [12-
15]. In addition, it is unclear how these patients can be identi-
fied early in the course of treatment.
 A few years ago, we reported the long-term outcomes of pa-
tients with invasive prolactinomas who were treated with bro-
mocriptine [16]. We documented that patients who achieved a 
tumor volume reduction (TVR) of at least 25% with NP at 3 
months had a high probability of achieving a long-term com-
plete response (CR), defined as a TVR of at least 50% with 
sustained NP. However, patients who were treated with CAB 
as a first-line therapy could not be included because CAB was 
a newly introduced and expensive drug in Korea at that time.
 In this study, we describe the results of CAB administration 
as a first-line treatment for 44 patients with macroprolactino-
mas who were followed for a median of 16 months. To identi-
fy early predictors of long-term response to CAB, we analyzed 
the influence of initial clinical parameters and early response 
to CAB on later outcomes. We also evaluated which treatment 
factors could affect the patient outcomes.
METHODS
Patients
We conducted a 6-year retrospective study of patients with 
macroprolactinomas who were treated with CAB as a primary 
drug at Severance Hospital, Seoul, Korea between 2008 and 
2013. Macroprolactinoma was defined as (1) a PRL level of at 
least 150 ng/mL and (2) a maximal diameter of at least 1 cm 
on baseline magnetic resonance imaging (MRI) scans of the 
sellar area. To evaluate the relationship between early and late 
parameters, the following additional inclusion criteria were 
applied: (1) a full dataset of pituitary hormone assays (includ-
ing PRL) and sella MRI at baseline, (2) follow-up PRL assay 
and MRI after 3 months of CAB treatment, and (3) total fol-
low-up duration of at least 12 months. 
Treatment and response assessment
In all cases, oral CAB was started at a low dose (1 to 1.5 mg/
wk), and the dosage was gradually increased to 1.5 to 4 mg/
wk within 2 to 4 weeks. The increased dose was maintained 
for 3 months after treatment initiation to ensure a sufficient 
period of exposure to CAB. Evaluations of response occurred 
after 3 months, and the dose of CAB and interval of follow-up 
were continuously adjusted in consideration of response, toler-
ance, and other clinical indicators. For patients with good re-
sponse and tolerance, reduction of CAB dose was carefully at-
tempted with a relatively long interval of follow-up. For pa-
tients with poor response, a higher dose of CAB and a short 
interval of follow-up were employed. Because the follow-up 
intervals and treatment durations of the patients varied, three 
representative time points of response assessment were retro-
spectively defined as follows: early assessment, when the first 
sella MRI and PRL assay were performed after 3 months of 
CAB treatment; late assessment, when the first sella MRI and 
PRL assay were performed 12 to 24 months after treatment; 
and last assessment, when the last sella MRI and PRL assay 
were performed. Tumor volume was calculated according to 
Di Chiro and Nelson’s formula: volume=height×length×
width×π/6 [17]. The degree of response was assessed using 
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TVR and NP. When evaluating the relationship between early 
response and later outcomes, we used group criteria according 
to the early response to CAB, as suggested in our previous ar-
ticle [16]: group 1, TVR ≥25% with NP; group 2, TVR ≥
25% without NP; group 3, TVR <25% with NP; and group 4, 
TVR <25% without NP [16]. A successful response at the late 
or last assessment was defined as follows: volume response, 
TVR ≥50% without surgery; PRL response, NP without sur-
gery; and CR, volume response with PRL response.
PRL assays
Serum PRL levels were measured via chemiluminescence im-
munoassay using commercial kits (Beckman Coulter, Brea, 
CA, USA). The within-run and total coefficients of variation 
for PRL concentrations were 3.66% and 3.77%, respectively. 
PRL levels <15 ng/mL for males and <25 ng/mL for females 
were regarded as normal. If serum PRL levels were normal or 
mildly elevated, PRL was measured again in diluted serum 
samples to exclude the hook effect, which can cause falsely 
low results [18,19].
Statistical analysis
Data were presented as the median (interquartile range) or the 
mean±SD. The relationship between early response and late 
or last response was analyzed using the Pearson correlation 
coefficient and multiple linear regression tests. The Student t 
test, Kruskal-Wallis test, Mann-Whitney U test, and Fisher ex-
act test were used to compare multiple groups. The relation-
ship between tumor volume or PRL levels at baseline and 
TVR, PRL levels, or the maintained dose of CAB after treat-
ment was analyzed using the Spearman correlation coefficient. 
Statistical analyses were performed using SPSS version 20 
(IBM Co., Armonk, NY, USA). Values of P<0.05 were con-
sidered statistically significant.
RESULTS
Baseline characteristics and overall treatment outcomes
Of 66 patients with macroprolactinomas who were treated 
with CAB as a primary drug during the study period, 47 pa-
tients were followed for at least 1 year from the initial admin-
istration of CAB to the end of the data collection. One patient 
was lost to follow-up before 12 months, and two female pa-
tients who became pregnant less than 12 months into CAB 
treatment were also excluded because CAB had to be discon-
tinued irrespective of tumor size and PRL level. Finally, in to-
tal, 44 patients, including 28 males (63.6%), were included in 
the study (Tables 1, 2). The mean age of the patients was 36.8 
years, and the median follow-up duration was 16 months (in-
terquartile range, 15 to 25.5). Eleven patients (25%) had visual 
field defects, and 28 patients (61.4%) complained of sexual 
dysfunction including impotence, oligomenorrhea/amenor-
rhea, and/or infertility. The patients also complained of head-
ache and dizziness (n=12, 27.3%), ocular movement abnor-
malities (n=2, 4.5%), and galactorrhea (n=6, 13.6%). The me-
dian PRL level and median tumor volume were 796.7 ng/dL 
(range, 202.5 to 2,431.3) and 3.71 cm3 (range, 1.60 to 11.51), 
respectively. Tumor invasion of the cavernous sinus was noted 
in 20 patients (45.5%). Most patients (n=40, 90.9%) displayed 
sex hormone deficiency, defined as a testosterone level below 
the lower limit of the normal population for males, oligomen-
orrhea/amenorrhea in premenopausal females, and an inappro-
priately low gonadotropin level in postmenopausal females. 
Five patients (11.4%) displayed growth hormone (GH) defi-
ciency, defined as a lower serum insulin-like growth factor 1 
(IGF-1) level than the age- and sex-specific lower limit of the 
normal population, whereas secondary hypothyroidism and 
adrenal insufficiency were found in one patient and zero pa-
tients, respectively. Compared with female patients, male pa-
tients were older (41.5 years vs. 28.5 years, P<0.001), less 
likely to complain of sexual dysfunction (46.4% vs. 87.5%, P=  
0.010), and more likely to have a visual field defect (39.3% vs. 
0%, P=0.003), and they displayed higher tumor volume (10.64 
cm3 vs. 0.87 cm3, P<0.001) and PRL level (923.3 ng/mL 
vs.428.5 ng/mL, P=0.023).
 At the last assessment, a volume response, PRL response, 
and CR were achieved by 35 (79.5%), 36 (81.8%), and 31 pa-
tients (70.5%), respectively (Table 1). Two patients who ex-
hibited transient mild PRL elevation (patients no. 18 and 24, 
who had PRL levels of 52.3 and 33.6 ng/mL, respectively) 
showed very poor drug compliance at the last assessment, but 
were regarded as having achieved a PRL response. Four pa-
tients (9.1%) underwent surgery in their treatment courses, 
and the median TVR of the patients who did not undergo sur-
gery was 74.7% (range, 61.7 to 85.4).
Influence of baseline tumor burden on outcomes
Neither the baseline tumor volume nor PRL level were direct-
ly correlated with TVR or PRL level at the early, late, and last 
assessments (Spearman correlation coefficients, all P>0.05). 
However, six patients with large tumors (larger group), whose 
baseline tumor volume exceeded 18 cm3 and whose PRL level 
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exceeded 2,000 ng/mL, displayed higher PRL levels than pa-
tients with smaller tumors (smaller group) 3 months after 
treatment (22.9 ng/mL vs. 1.6 ng/mL, P=0.043) (Fig. 1A). In-
terestingly, these differences in PRL levels between groups 
lost their statistical significance at 9 months (Fig. 1A), and the 
TVR of patients who did and did not undergo surgery did not 
vary between the groups during the entire treatment course 
(Fig. 1B).
Relationships between early response and late or last 
response
To assess the influence of early response on late or last re-
sponse, we primarily categorized patients into four groups ac-
cording to their early responses to CAB. Of the total 44 pa-
tients, 29 patients were included in group 1 (TVR ≥25% with 
NP), eight in group 2 (TVR ≥25% without NP), five in group 
3 (TVR <25% with NP), and two in group 4 (TVR <25% 
without NP) (Fig. 2A). Most patients in group 1 (93.1%) 
achieved a CR as expected, but two patients (6.9%) did not 
achieve TVR ≥50% until the last assessment. Four of eight 
patients (50%) in group 2 eventually achieved a CR, whereas 
no patients in groups 3 and 4 achieved a CR. The proportion 
of CRs significantly differed between the groups (group 1 vs. 
2 vs. 3 vs. 4; 93.1% vs. 50% vs. 0% vs. 0%; P<0.001). The 
last maintenance dose of CAB differed according to the last 
responses (CR vs. volume response without NP vs. PRL re-
sponse without TVR ≥50% vs. surgery; 1.5 mg/wk (range, 1.0 
to 2.0) vs. 4.5 mg/wk (range, 2.75 to 4.5) vs. 2.0 mg/wk 
(range, 1.0 to 2.0) vs. 0.5 mg/wk (range, 0.0 to 0.7); overall 
P=0.006), but no differences were observed between the four 
groups according to early responses (P=0.109).
 We conducted further analysis of change in PRL levels to 
Table 1. Summary of 44 Patients with Macroprolactinomas
Variable Total (n=44) Female (n=16) Male (n=28) P value
Demographic characteristicsa
   Age, yr        36.8±12.0       28.5±12.0        41.5±9.3 <0.001
Symptom and signb
   Visual defect 11 (25.0) 0 (0) 11 (39.3) 0.003
   Sexual dysfunction 27 (61.4) 14 (87.5) 13 (46.4) 0.010
   Headache and dizziness 12 (27.3) 2 (12.5) 10 (35.7) 0.160
   Ocular movement abnormality 2 (4.5) 0 (0) 2 (7.1) 0.526
   Galactorrhea 6 (13.6) 4 (25) 2 (7.1) 0.169
Baseline hormonal deficiencyb
   Sex hormone deficiency 40 (90.9) 15 (93.8) 25 (89.3) 1.000
   GH deficiency 5 (11.4) 1 (6.3) 4 (14.3) 0.638
   Secondary hypothyroidism 1 (2.3) 1 (6.3) 0 (0) 0.364
Baseline prolactin and tumor volumec
   Prolactin, ng/mL 796.7 (202.5–2,431.3) 428.5 (165.6–932.6) 923.3 (545.6–3,072.3) 0.023
   Tumor volume, cm3 3.71 (1.60–11.51) 0.87 (0.53–2.99) 10.64 (3.13–13.0) <0.001
Final results of treatmentb
   Follow-up duration, mo 16 (15–25.5) 15 (15–22.5) 20.5 (15–29) 0.299
   Tumor volume reduction without surgery, %d 74.7 (61.7–85.4) 82.6 (72.9–86.6) 69.6 (56.6–80.6) 0.040
   Volume response 35 (79.5) 15 (93.8) 20 (71.4) 0.124
   Prolactin response 36 (81.8) 13 (81.3) 23 (82.1) 1.000
   Complete response 31 (70.5) 13 (81.3) 18 (64.3) 0.314
   Surgery 4 (9.1) 1 (6.3) 3 (10.7) 1.000
Values are expressed as mean±SD, number (%), or median (interquartile range).
GH, growth hormone.
aThe Student t test was used for parametric and nonparametric analyses, respectively; bThe Fisher exact test was used for categorical data analyses; 
cThe Mann-Whitney U test was used for parametric and nonparametric analyses, respectively; dPatients who underwent surgery before the final as-
sessment were excluded.
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identify the distinguishing characteristics of the patients in 
group 2 that eventually achieved a CR (Fig. 2B). Of the four 
patients who achieved NP, three patients displayed normal 
PRL levels at 6 to 9 months (patients no. 32, 33, and 37). The 
remaining patient, who had a giant prolactinoma (patient no. 
31; maximum tumor diameter 4.8 cm, tumor volume 20.4 cm3, 
Fig. 1. Changes in prolactin (PRL) levels and tumor volume reduction (TVR) in two groups according to baseline tumor volume. Black 
lines indicate patients with larger tumors (larger group); gray lines, patients with smaller tumors (smaller group). The cutoff between the 
two groups was a baseline tumor volume of 18 cm3. Each P value between the groups was calculated at each time point with the Mann-
Whitney U test. At each time point, the patients who underwent surgery before the assessment were excluded. (A) Changes in median 
PRL levels. (B) Changes in median TVR.
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Fig. 2. Fate of 44 patients with macroprolactinomas according to 
early response. (A) Overall progress of patients according to cate-
gorization by early response. (B) Prolactin (PRL) levels of the pa-
tients in group 2. Black line indicates patients who eventually 
achieved normalization of prolactin level (NP; delayed response 
subgroup); gray line, patients who did not achieve NP (sustained 
resistance subgroup). TVR, tumor volume reduction. aP<0.05 be-
tween the subgroups, the P value was calculated with the Mann-
Whitney U test.
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and PRL level 8,759 ng/mL at baseline), maintained a slightly 
supranormal range PRL until 15 months (18.6 ng/mL at 9 
months and 19.5 ng/mL at 15 months), but exhibited NP at 21 
months. Median PRL levels did not differ between the patients 
who achieved NP (delayed response subgroup, n=4) and those 
who did not achieve NP (sustained resistance subgroup, n=4) 
until 3 months (1,947.4 ng/mL vs. 813.5 ng/mL, P=0.886 at 
baseline; 55.3 ng/mL vs. 115.3 ng/mL, P=0.686). However, a 
meaningful difference in median PRL levels between the two 
subgroups could also be observed after 9 months of CAB 
treatment (median PRL level: 13.0 ng/mL vs. 117.9 ng/mL, 
P=0.029). Median TVR did not vary between the subgroups 
(59.1% vs. 65.3%, P=0.486 at 3 months; 81.9% vs. 74.7%, 
P=0.200 at 15 months).
 We also attempted to determine whether the absolute value 
of early TVR itself is predictive of response or whether only a 
certain cutoff such as 25% is meaningful. Pearson correlation 
analysis demonstrated that late TVR had a very strong correla-
tion with early TVR (R=0.869, P<0.001) according to the fol-
lowing regression equation: late TVR=0.851×early TVR+ 
26.606 (Fig. 3). Last TVR also displayed a correlation with 
early TVR, although the strength of the correlation was slightly 
lower (R=0.785, P<0.001). Multiple regression analysis was 
subsequently performed using sex, natural logarithm of the 
CAB maintenance duration between early and late assessment 
(Ln [weeks]), and cumulative dose of CAB between early and 
late assessments (mg) as independent variables. In this analy-
sis, a greater TVR at the early assessment and a longer CAB 
maintenance duration were independent predictors for greater 
TVR at the late assessment (β=0.849, P<0.001; and β for Ln 
[weeks], 16.978, P=0.016, respectively), whereas sex and cu-
mulative dose of CAB were not predictive (P=0.074 and P=  
0.613, respectively).
Influence of surgery on the final maintenance dose of CAB
Because the patients who underwent surgery maintained the 
lowest dose of CAB (Fig. 2A), we sought to confirm whether 
surgery could independently reduce CAB dose. Thus, we per-
formed multiple linear regression analysis with four indepen-
dent variables as follows: undergoing surgery, baseline PRL 
level (mg/mL), 1/baseline volume (1/cm3), and natural loga-
rithm of the treatment duration (Ln [months]). Baseline vol-
ume was transformed reciprocally to ensure the linearity of the 
model. Analysis confirmed that undergoing surgery (β=  
−1.181, P=0.013), a lower baseline PRL level (β=0.161, P=  
0.008), a smaller baseline volume (β for 1/baseline volume=  
−0.448, P=0.026), and a longer treatment duration (β for Ln 
[months]=−0.882, P=0.010) were independent predictors for 
a lower dose of CAB at the last assessment.
Summary of patients who underwent surgery
Four patients underwent transsphenoidal surgery (Table 3; pa-
tient nos. 38, 42, 43, and 44). The first patient (patient no. 38) 
underwent surgery after 3 months of CAB treatment because 
of acute hemorrhage in the tumor accompanied by severe 
headache. Immunohistochemical analysis for all pituitary hor-
mones including PRL was negative, but the PRL result was re-
garded to be false-negative due to destruction of tumor cells 
following acute hemorrhage, as a nonfunctioning pituitary ad-
enoma could not explain the patient’s extremely high baseline 
PRL level (2,042 ng/mL). His headache resolved completely 
after surgery, although he developed panhypopituitarism. His 
CAB dose was reduced from 3 to 0.7 mg/wk, and his serum 
PRL levels were within the reference range. The second pa-
tient (patient no. 43) underwent surgery at 5 months because 
of a progressive visual field defect and diplopia. Immunohis-
tochemical analysis of the excised tumor revealed PRL immu-
noreactivity. His symptoms were dramatically improved after 
surgery, although panhypopituitarism developed. The patient 
was able to discontinue CAB with sustained NP, and MRI re-
vealed no residual tumor. The third patient (patient no. 42) un-
derwent elective surgery after 12 months of CAB treatment 
owing to CAB resistance. Her early TVR was only 5.7%, and 
her preoperative PRL level was 168.6 ng/mL. Immunohisto-
chemical analysis demonstrated PRL reactivity. She was able 
to discontinue CAB with sustained NP and no evidence of a 
residual tumor. The fourth patient (patient no. 44) also under-
Fig. 3. Correlation between late tumor volume reduction (TVR) 
and early TVR. The Pearson correlation analysis was used for sta-
tistical analysis.
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went elective surgery after 16 months of CAB treatment due 
to CAB resistance. His tumor size had increased by 2.1% de-
spite 3 months of CAB treatment, and it continued to grow af-
ter 12 additional months of treatment without NP. Immunohis-
tochemical staining revealed immunoreactivity for PRL. Post-
operative MRI could not confirm whether there was residual 
tumor or only postoperative changes. PRL levels were not 
normalized despite surgery; however, CAB dose was marked-
ly decreased (from 3 to 1 mg/wk) with a partial reduction in 
serum PRL level (from 699.4 to 393.8 ng/mL).
 Overall, none of the patients achieved TVR ≥25% at 3 
months, including those with (patient no. 38 and 42) and those 
without (patient no. 43 and 44) NP. CAB dose was decreased 
after surgery, and two patients were able to discontinue CAB 
without evidence of residual tumor or PRL elevation.
Changes in the pituitary hormone levels and haracteristics 
of patients who did not exhibit  testosterone level recovery
Among the patients who did not undergo surgery, CAB treat-
ment improved baseline abnormalities of other pituitary hor-
mones in most. All subnormal IGF-1 levels (patient no. 6, 8, 9, 
13, and 24) and secondary hypothyroidism (patient no. 34) 
were gradually restored. All premenopausal women with oli-
gomenorrhea/amenorrhea demonstrated improvement of 
symptoms following reduction of PRL levels, and the subnor-
mal gonadotropin level of one postmenopausal woman was 
also improved. However, six male patients with NP and two 
male patients without NP displayed subnormal serum testos-
terone levels at the last assessment.
 To elucidate the early characteristics of patients who could 
not achieve normalization of testosterone levels despite NP, 
we compared various clinical parameters of these patients 
(subnormal group, n=6) with those of male patients with nor-
mal testosterone levels and NP at the last assessment (normal 
group, n=16). Three patients who underwent surgery and one 
patient who received exogenous testosterone replacement be-
fore the first visit to our institution were excluded from this 
analysis to minimize confounding factors. The subnormal 
group had lower baseline IGF-1 (median 112.0 ng/mL vs. 
212.1 ng/mL, P=0.013) and testosterone levels (median 57.9 
ng/dL vs. 159.4 ng/dL, P=0.010) than the normal group. Pa-
tients in the subnormal group tended to be older (48.4 years 
Table 3. Summary of Patients Who Underwent Surgery
Patient 38 Patient 42 Patient 43 Patient 44
Age, yr 27.5 22.5 51.4 42.2
Sex M F M M
Cavernous sinus invasion No No Yes Yes
Visual field defect Yes No Yes No
Ocular movement Abnormality No No Yes No
Baseline volume, cm3 17.67 0.35 22.06 2.34
Baseline PRL level, ng/mL 2,042 196.3 2,820.5 317.1
TVR at 3 mo, % −3.9 5.7 22.1 -2.1
Preoperative PRL level, ng/mL 0.5 168.6 23.1 699.4
Preoperative dose of CAB, mg/wk 3 3 3 3
Reason for surgery Acute hemorrhage 
with headache
No change of tumor size Sustained visual field 
defect and diplopia
Increased tumor size
Timing of surgery, mo of treatment 3 12 5 16
Immunohistochemistry All (−)a PRL (+) PRL (+) PRL (+)
Residual tumor on MRI No No No Uncertain
Last PRL level, ng/mL 7.9 15.3 13.2 393.8
Last CAB dose, mg/wk 0.7 0 0 1
Last hormone deficiency GH/TSH/cortisol None Sex/GH/TSH/cortisol None
Follow-up duration, mo 32 15 15 17
M, male; F, female; PRL, prolactin; TVR, tumor volume reduction; CAB, cabergoline; MRI, magnetic resonance imaging; GH, growth hormone; 
TSH, thyroid-stimulating hormone.
aThis was regarded as a false-negative result owing to acute hemorrhage.
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vs. 39.8 years, P=0.052), and this group had a higher propor-
tion of patients with age-specific subnormal IGF-1 levels 
(50% vs. 6.3%, P=0.046). Baseline tumor volume, PRL lev-
els, proportion of patients with symptoms related to volume 
effects, and responses to CAB in terms of TVR and residual 
volume did not differ between the groups.
DISCUSSION
We described the clinical outcomes of 44 patients with macro-
prolactinomas who were treated with CAB, and this is the first 
report on CAB treatment in Korea with a relatively large sam-
ple size. Only one previous article on the efficacy of CAB in 
Korea has been published [20]. This study concluded that 
CAB could be used effectively even for invasive giant prolac-
tinoma; however, its sample size was relatively small (n=10), 
and patients treated with other modalities such as transsphe-
noidal approach during their treatment courses were excluded. 
In our study, the CR rate (TVR ≥50% with NP) of CAB treat-
ment at the last assessment was 70.5% (total 31/44; group 1, 
n=27; group 2, n=4). This rate was not superior to the CR rate 
of bromocriptine treatment (CR rate, 69.4%) that we reported 
previously, but this appears to have resulted from the shorter 
follow-up duration (15 months vs. 44 months) [16]. Previous 
reports of the treatment results of CAB varied widely accord-
ing to different inclusion criteria, cutoff of “responsiveness,” 
and treatment duration [1,19,21]. In a retrospective study of 
455 patients with hyperprolactinemia, TVR ≥50% was noted 
in 31% of 190 evaluable patients and NP was achieved in 77% 
of 181 patients with macroprolactinomas after a median of 28 
months of CAB treatment [22]. In another retrospective study 
of 56 de novo patients with macroprolactinoma, significant tu-
mor reduction (defined as a ≥30% reduction of the maximal 
tumor diameter) was achieved in 89.1% of patients, and NP 
was achieved in 82.1% of patients [7]. In a prospective study 
of 26 drug-naive patients with macroprolactinomas, NP was 
achieved in 80.7% of patients after 6 months of treatment, the 
mean volume was reduced by 67.5% after 1 year, and the 
mean TVR was 92.1% after 3 years of CAB treatment [23]. 
Our outcomes regarding TVR and NP were in line with the 
findings of these previous reports.
 In our study, we primarily focused on discovering early in-
dicators that could reliably predict long-term response to 
CAB. Early identification of CAB-resistant patients is valu-
able considering the following facts. First, recent large studies 
of patients with CAB-resistant prolactinomas demonstrated 
that pharmacological resistance to CAB is associated with 
more aggressive disease, the potential risk of malignant evolu-
tion, and genetic predisposition to pituitary adenomas [15]. 
Second, there are concerns about the safety of long-term high-
dose CAB treatment in patients with resistant prolactinomas. 
CAB was found to increase the frequency of valvular heart 
disease in a dose-dependent manner in studies of patients with 
Parkinson disease [24-27]. Although many studies indicated 
that a lower dose of CAB used in treatment for hyperprolac-
tinemia or prolactinoma was not related to valvular dysfunc-
tion [28], some studies reported an increased risk of tricuspid 
valve dysfunction in patients with prolactinomas who were 
treated with long-term, high-dose CAB regimens [29,30]. Fi-
nally, long-term treatment with DAs may cause peritumoral 
fibrosis, which makes removal of the entire tumor difficult, al-
though it is unclear whether this phenomenon also occurs as a 
result of CAB treatment [31,32].
 In our study, we determined that grouping patients after 3 
months of CAB treatment using TVR ≥25% and NP criteria 
was a potentially reliable approach. Groups with TVR ≥25% 
with NP, TVR ≥25% without NP, and TVR <25% at 3 months 
after CAB treatment could be regarded as having early respon-
siveness, early partial resistance, and early resistance respec-
tively, considering the different long-term CR rates of 93.1%, 
50%, and 0%, respectively. We reconfirmed that TVR=25% at 
3 months might be a reliable cutoff because TVR at 3 months 
was very strongly correlated (R>0.8) with TVR at 15 months, 
and the estimated regression equation revealed that a cutoff re-
sistance of TVR=50% at 15 months [11] corresponded to 
TVR=25% at 3 months. These results are in line with our pre-
vious reports demonstrating that TVR ≥25% and NP after 3 
months of bromocriptine treatment are useful predictors of re-
sponsiveness to DAs [16].
 In addition, patients with early partial resistance should be 
reassessed after several months to confirm whether they ach-
ieved a delayed response. Among patients with TVR ≥25% 
without NP at 3 months, the PRL levels of patients who 
achieved a CR were lower than those of patients who did not 
achieve a CR after 9 months. This is similar to the results ob-
served for bromocriptine treatment, in which three of five pa-
tients with TVR ≥25% without NP at 3 months achieved NP 
at 5 to 9 months [16]. Moreover, patients with giant prolacti-
nomas might require a longer treatment duration to achieve 
NP than patients with smaller tumors even if the giant tumors 
exhibit sufficient responsiveness to CAB. The patients with 
the largest tumors and very high PRL levels displayed higher 
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PRL levels at 3 months than other patients, but, after 9 months 
of treatment, they achieved similar TVR rates and PRL levels 
as patients with smaller tumors. Similarly, in a study of 10 
male patients with invasive giant prolactinomas (tumor diam-
eter >4 cm with PRL levels >1,000 ng/mL), none achieved 
PRL levels <15 ng/mL at 3 months, although six patients 
(60%) exhibited PRL levels <15 ng/mL at the final assess-
ment with continuous CAB treatment [20].
 The most effective treatment modality for patients with re-
sistance to standard-dose CAB remains unclear. In this situa-
tion, high doses of CAB, transsphenoidal surgery, and occa-
sionally radiotherapy can be applied, and temozolomide thera-
py can be used for patients with malignant prolactinomas 
[8,19,21]. Recently, Vroonen et al. [15] reviewed the outcomes 
of 92 patients with resistance to CAB, defined as a failure to 
achieve NP on a CAB dose of 2.0 mg/wk. Of the 17 patients 
treated with high-dose CAB regimens (≥3.5 mg/wk) without 
surgery, only five patients (26.3%) achieved NP. Surgery dem-
onstrated significant usefulness for controlling PRL levels and 
reducing CAB dose, whereas radiotherapy did not have a sig-
nificant benefit. Based on these results, the authors suggested 
that surgery could improve the outcomes of patients with CAB 
resistance [15].
 In our study, surgery demonstrated its usefulness for disease 
control and reducing CAB dose. Three of the four patients 
who underwent surgical interventions achieved complete tu-
mor resolution on MRI with NP even though they had TVR 
<25% and/or no NP at 3 months. Two patients were able to 
discontinue CAB early, and multiple regression analysis of all 
the 44 patients also revealed that surgery could reduce CAB 
dose independently. Conversely, a higher cumulative dose of 
CAB did not alter TVR upon correction for treatment dura-
tion. CAB inhibits PRL production in a dose-dependent man-
ner [1], and resistance to DAs is occasionally overcome by 
high-dose CAB treatment [13,14]. Therefore, guidelines sug-
gest escalating the CAB dose in patients with resistance [8,19]. 
This difference between our results and the results of previous 
reports may be due to the relatively narrow range of our CAB 
dose. A CAB dose exceeding 3 mg/wk is rarely necessary for 
prolactinomas [1,8,19], but doses as high as 11 mg/wk may be 
required to overcome pharmacological resistance [13,14]. In 
our study, the median peak CAB dose was 3 mg/wk with an 
interquartile range of only 1 mg, and this dose may be insuffi-
cient to reverse the resistance of some patients. However, it 
should be noted that a markedly increased CAB dose might be 
associated with cardiac valve disease, as discussed previously.
 Another interesting finding was that baseline IGF-1 level 
was associated with final restoration of sex hormones. Unlike 
other pituitary hormones, suppression of sex hormones can be 
a result of hyperprolactinemia-induced hypogonadism and 
compression of the gonadotropic cells by tumors [21]. How-
ever, CAB treatment results in rapid normalization or marked 
reduction of PRL levels in most patients, and, thus, persistent 
subnormal sex hormone levels would primarily result from 
volume effects rather than hyperprolactinemia. In our study, 
six of the eight nonsurgically-treated male patients with hypo-
gonadism at the last assessment displayed NP; thus, these pa-
tients were regarded as having hypogonadism induced by 
compression. In terms of pituitary hormone deficits induced 
by tumors, GH deficiency is the second most common deficit 
after hypogonadism [33-36]. In our study, six patients with 
persistent hypogonadism despite NP had lower IGF-1 levels at 
diagnosis than other male patients, whereas their baseline tu-
mor volume or residual volume after treatment was not larger. 
These findings suggest that a low IGF-1 level at diagnosis 
might be a useful indicator for predicting persistent hypogo-
nadism induced by volume effects, which might not be direct-
ly proportional to tumor size itself.
 This study has some limitations. First, this study is a retro-
spective, single-center study, and fully standardized protocols 
were not available for adjusting CAB dose or follow-up inter-
val. For collection of further precise data, a prospective study 
with a preset protocol is warranted. Second, the prevalence of 
adrenal insufficiency could have been underestimated, be-
cause stimulation tests were not routinely performed. Howev-
er, the basal pituitary hormone test is used as an important 
screening test in clinical fields, and gonadal function and thy-
roid function can be interpreted from the basal hormone test 
and symptoms/signs. Thus, the descriptive data of the basal 
hormone test may be a useful indicator. Third, 16 months of 
follow-up might be relatively short to represent long-term re-
sponse. Further cumulative data collection on CAB treatment 
would provide us with additional information.
 In conclusion, CAB treatment was very effective in two-
thirds of patients with macroprolactinomas. Assessing re-
sponse using TVR and NP after 3 months of treatment is a 
useful approach for predicting long-term response and resis-
tance to CAB. When patients achieve TVR ≥25% without NP 
at 3 months, the assessment of resistance should be delayed 
for several months to rule out a delayed response, especially in 
patients with large tumors. Surgical treatment can help reduce 
CAB dose and contribute to successful disease control, and 
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should be considered in CAB-resistant patients.
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